In 2024, the global allergy diagnostics market was estimated at $5.3 billion and is set to reach $9.8 billion by 2029, growing at a CAGR of 11.0%. This study provides insights into industry trends, pricing analysis, patent analysis, and key stakeholder activities, including conference and webinar discussions and buying behavior.
Browse in-depth TOC on "Allergy Diagnostics Market"
248 - Tables
57 - Figures
307 – Pages
The consumables segment is expected to account for the largest share in 2023.
The Allergy Diagnostics market, by product service, has been segmented into consumables, instruments, and services. The consumables segment accounted for the largest share of the Allergy Diagnostics market in 2023. This segment is also anticipated to experience significant growth over the projected period. The increasing demand for rapid diagnosis of allergic patients which is driven by increasing number of allergic cases can be attributed for the larger share of this segment during the forecast period.
In Vivo test segment held the largest market share in the Allergy Diagnostics market.
Based on the test type, the Allergy Diagnostics market is segmented into in vivo tests and in vitro tests. In 2023, the in vivo tests segment accounted for the largest share of the Allergy Diagnostics market. The growth of this segment is mainly driven by the growing adoption of various in vivo tests, such as skin prick tests which is considered as the first line of diagnosis for allergy and favorable government support and guidelines.
Inhaled allergy segment held the largest market share in the Allergy Diagnostics market.
Based on the allergen, the Allergy Diagnostics market is segmented into inhaled allergens, food allergens, drug allergens, and other allergens. In 2023, the inhaled allergens segment accounted for the largest share of the Allergy Diagnostics market due to the rising environmental pollution, rising home dust mites coupled with other factors such as pollen, fungus, mold, and dust, and switching lifestyles, including rise in indoor activities and exposure to indoor allergen.
North America dominates the global Allergy Diagnostics market
Based on the region, the Allergy Diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East Africa. North America market is driven by availability of technologically advanced products and growing research on allergy by companies and government. The Asia Pacific segment is projected to register the highest CAGR during the forecast period. Developing healthcare infrastructure, lifestyle changes and climatic conditions, increased ozone and industrial pollution levels, and the rising demand for quality medical care are some of the major factors driving the growth of this regional market.
Allergy Diagnostics Market Dynamics:
Drivers:
- High incidence and heavy economic burden of allergic diseases
Restraints:
- High pricing of allergy diagnostic instruments
Opportunities:
- Integration of AI in allergy diagnosis
Challenge:
- Shortage of allergists
Key Market Players of Allergy Diagnostics Industry:
Major players in Allergy Diagnostics market include Thermo Fisher Scientific Inc., (US), Siemens Healthineers AG (Germany), Danaher (US), and Canon, Inc. (Japan), Minaris Medical America, Inc. (US).
Recent Developments of Allergy Diagnostics Industry:
- In 2023, Canon has completed share transfer procedures with Resonac Corporation. This share transfer is intended to be used to purchase the Resonac subsidiaries Minaris Medical Co., Ltd. and Minaris Medical America, Inc. (collectively, "Minaris Medical"). After this share acquisition is finished, Minaris Medical—which runs companies that deal with automated analytical tools and in vitro diagnostic reagents—will be consolidated under Canon Medical.
- In 2023, Romer Labs Division Holding GmbH (Austria) acquired CPAK INTER Co., Ltd. (Thailand), a long-time distributor of Romer Labs solutions based in Bangkok. With the acquisition, Romer Labs has achieved yet another significant milestone in the quickly expanding Asian food safety industry.
- In 2022, The US Food Drug Administration (FDA) has cleared ImmunoCAP Specific IgE (sIgE) Allergen Components for use in in vitro diagnostic testing for wheat and sesame allergies, according to a statement from Thermo Fisher Scientific, Inc. (US).
Allergy Diagnostics Market - Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall Allergy Diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (global rise in prevalence and heavy economic burden of allergic illnesses, growing environmental pollution, and insurance coverage), restraints (high costs of analyzers and access is limited to healthcare services), opportunities (use of mHealth and integration of AI in allergy diagnosis), and challenges (a few number of allergists and challenges during diagnosis of allergy) influencing the growth of the Allergy Diagnostics market
- Product Development/Innovation: Detailed insights on upcoming technologies, research development activities, and new product service launches in the Allergy Diagnostics market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the Allergy Diagnostics market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Allergy Diagnostics market
- Competitive Assessment: In-depth assessment of market ranking, growth strategies, and service offerings of leading players like Thermo Fisher Scientific Inc., (US), Siemens Healthineers AG (Germany), Danaher (US), and Canon, Inc. (Japan) [Minaris Medical America, Inc. (US)], among others in the Allergy Diagnostics market strategies.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets Inc.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
UK +44-800-368-9399
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Content Source:
https://www.marketsandmarkets.com/PressReleases/allergy-diagnostics.asp
